LENZ Therapeutics, Inc. (LENZ) stock
LENZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3055% below fair value
$3.21−0.29 (-8.29%)
Close on Nov 18, 2026Market cap $100.86MP/E –Yield –
LENZ Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
LENZ Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$135.66M. For fiscal 2025 it was -$91.14M. The highest annual figure on record is -$13.50M in fiscal 2020.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$91.14M | – |
| FY2024 | Dec 31, 2024 | -$58.61M | – |
| FY2023 | Dec 31, 2023 | -$72.43M | – |
| FY2022 | Dec 31, 2022 | -$105.64M | – |
| FY2021 | Dec 31, 2021 | -$60.44M | – |
| FY2020 | Dec 31, 2020 | -$13.50M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$34.17M | – |
| Q1 FY2026 | Mar 31, 2026 | -$44.14M | – |
| Q4 FY2025 | Dec 31, 2025 | -$38.46M | – |
| Q3 FY2025 | Sep 30, 2025 | -$18.89M | – |
| Q2 FY2025 | Jun 30, 2025 | -$16.86M | – |
| Q1 FY2025 | Mar 31, 2025 | -$16.93M | – |
| Q4 FY2024 | Dec 31, 2024 | -$15.23M | – |
| Q3 FY2024 | Sep 30, 2024 | -$12.95M | – |
| Q2 FY2024 | Jun 30, 2024 | -$14.35M | – |
| Q1 FY2024 | Mar 31, 2024 | -$16.09M | – |
| Q4 FY2023 | Dec 31, 2023 | -$24.99M | – |
| Q3 FY2023 | Sep 30, 2023 | -$19.87M | – |
| Q2 FY2023 | Jun 30, 2023 | -$14.96M | – |
| Q1 FY2023 | Mar 31, 2023 | -$12.62M | – |
| Q4 FY2022 | Dec 31, 2022 | -$26.75M | – |
| Q3 FY2022 | Sep 30, 2022 | -$26.15M | – |
| Q2 FY2022 | Jun 30, 2022 | -$26.78M | – |
| Q1 FY2022 | Mar 31, 2022 | -$25.96M | – |
| Q4 FY2021 | Dec 31, 2021 | -$18.94M | – |
| Q3 FY2021 | Sep 30, 2021 | -$14.60M | – |
| Q2 FY2021 | Jun 30, 2021 | -$17.53M | – |
| Q1 FY2021 | Mar 31, 2021 | -$9.37M | – |
| Q4 FY2020 | Dec 31, 2020 | -$8.32M | – |
| Q3 FY2020 | Sep 30, 2020 | -$3.76M | – |
| Q2 FY2020 | Jun 30, 2020 | -$1.29M | – |
See a number that looks wrong?